About   Help   FAQ
Phenotypes Associated with This Genotype
Genotype
MGI:2662300
Allelic
Composition
Adcy5tm1Yish/Adcy5tm1Yish
Genetic
Background
involves: 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Adcy5tm1Yish mutation (0 available); any Adcy5 mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
behavior/neurological
• at 8-12 weeks of age, homozygotes display a significantly impaired performance on the accelerating Rotarod relative to wild-type mice, even after several trials
• administration of SKF38393 (a D1 dopaminergic agonist; 25 or 50 mg/kg), fails to improve Rotarod performance in both wild-type and mutant mice
• administration of cabergoline (0.2 or 1.0 mg/kg), a D2 dopaminergic agonist, selectively restores Rotarod performance of mutant mice to wild-type levels, but has no effect on wild-type mice
• no choleric or dystonic movements are observed in the tail suspension test
• at 8-12 weeks of age, homozygotes display a small but significant reduction in vertical open field locomotor activity relative to wild-type mice
• at 8-12 weeks of age, homozygotes show significant bradykinesia in the pole test; when mice are placed head upward on the top of a rough surfaced pole, both Tturn (the time until mice turn completely downward) and TLA (the time until mice climb down to the floor), are prolonged by 3-fold relative to wild-type values
• both SKF38393 and cabergoline improve pole test performance in mutant mice; the latter induces a drastic improvement even with a lower dose (0.2 mg/kg)
• at 8-12 weeks of age, homozygotes display a small but significant reduction in horizontal open field locomotor activity relative to wild-type mice
• administration of SKF38393 (25 or 50 mg/kg), a D1 dopaminergic agonist, elicits a significantly greater ("supersensitive") locomotor activity response in mutant mice relative to wild-type mice
• administration of cabergoline (0.2 or 1.0 mg/kg), a D2 dopaminergic agonist, has no effect on locomotor activity, although both wild-type and mutant mice display a tendency of small increases

homeostasis/metabolism
• at 8-12 weeks of age, homozygotes display a marked loss of adenylyl cyclase activity in a striatum-specific manner with a small increase in the expression of other adenylyl cyclase isoforms
• D1 dopaminergic agonist-stimulated adenylyl cyclase activity is attenuated, along with a reduction in the expression of the D1 dopaminergic receptor and Gsalpha
• D2 dopaminergic agonist-mediated inhibition of adenylyl cyclase activity is blunted

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
Parkinson's disease DOID:14330 OMIM:607688
OMIM:610297
OMIM:613643
OMIM:614251
OMIM:PS168600
J:83301


Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
11/12/2019
MGI 6.14
The Jackson Laboratory